2. Academic Validation
  3. Novel Macrocyclic Compounds Targeting KRAS Mutations for Cancer Treatment

Novel Macrocyclic Compounds Targeting KRAS Mutations for Cancer Treatment

  • ACS Med Chem Lett. 2026 Feb 9;17(3):613-615. doi: 10.1021/acsmedchemlett.6c00032.
Lingxin Meng 1,  Steven H Liang 1 2
Affiliations

Affiliations

  • 1 Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
  • 2 Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States.
PMID: 41847639 DOI: 10.1021/acsmedchemlett.6c00032
Abstract

This patent provides novel macrocycle compounds that inhibit key mutants (G12D/G13D) of the KRAS oncogene, which is the most frequently mutated in human cancers. These compounds, along with their pharmaceutical compositions and protein complexes, are intended for the treatment of cancers driven by these mutations.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z